Last updated: February 15, 2026
What Is the Market Status and Price Projection for NDC 24385-0077?
NDC 24385-0077 corresponds to Vonjo (pacritinib), developed by Canadian company Cantex Pharmaceuticals, approved by the FDA for myelofibrosis, a rare bone marrow disorder. Its market entry, competitive landscape, current pricing, and future price trends are analyzed below.
Market Overview
Indication and Use:
Vonjo targets systemic myelofibrosis patients with platelet counts below 50,000/μL. Approved in February 2022, it is positioned as an alternative to JAK inhibitors like ruxolitinib and fedratinib, especially for high-risk patients with thrombocytopenia.
Market Size:
The global myelofibrosis market is estimated at $1.5 billion as of 2022, with forecasted growth at approximately 5.5% CAGR to reach $2.05 billion by 2027. The subset of patients eligible for Vonjo, characterized by severe thrombocytopenia, accounts for roughly 10-15% of this population.
Competitive Landscape:
Current therapies include JAK inhibitors, notably ruxolitinib (marketed as Jakafi), with sales exceeding $950 million in 2021. Vonjo faces competition from these established agents but offers an edge in thrombocytopenic populations.
Pricing Analysis
Current Price Points:
- In the United States, the listed wholesale acquisition cost (WAC) for Vonjo is approximately $17,400 per month per patient, equating to about $208,800 annually.
- This aligns with other niche oncology drugs targeting rare diseases, which often command high prices due to limited patient populations and high R&D costs.
Pricing Strategy Rationale:
- Premium pricing reflects unmet medical needs in severe thrombocytopenic myelofibrosis cases that lack effective treatments.
- Payer coverage and discounts vary across regions, with commercial insurers negotiating discounts that may reduce net prices by 20-30%.
International Price Trends:
- In countries outside the U.S., prices tend to be lower, ranging from $10,000 to $15,000 per month, influenced by reimbursement policies and healthcare system structures.
Future Price Projections
Factors Influencing Price Changes:
- Market Penetration: As Vonjo expands access and gains broader indications, volume increases may support price reductions.
- Payer Negotiations: Broader coverage, especially in Medicaid and Medicare, could pressure pricing downward.
- Competitive Dynamics: Introduction of biosimilars or new targeted therapies could impact list prices.
- Regulatory Changes: Alternative approval pathways or cost-control policies in the U.S. and other regions may lead to price caps or increased discounts.
Projected Trends (2023-2028):
- Short-term (next 1-2 years): Stable list price at approximately $17,400/month due to limited competition.
- Medium-term (3-5 years): Anticipated slight declines of 5-10% in net prices owing to expanded market access and payer negotiations.
- Long-term (beyond 5 years): Potential for significant price reductions if biosimilar competition or new therapies emerge, or if price caps are implemented.
Regulatory and Policy Impact
- The Orphan Drug designation permits high pricing due to small patient population.
- Reimbursement policies evolving towards value-based care could pressure manufacturers to justify premium prices with real-world outcomes data.
Summary
| Attribute |
Details |
| Current Price |
$17,400/month (~$208,800/year) (U.S. wholesale) |
| Estimated Market Size |
$1.5 billion globally (2022) |
| Projected Price Trend |
Stable short term, slight decline over 3-5 years |
| Key Influencers |
Market expansion, payer negotiations, competition |
Key Takeaways
- Vonjo's high list price reflects its niche indication and unmet need in severe thrombocytopenic myelofibrosis.
- The drug's market is limited but growing, supporting sustained premium pricing.
- Price reductions are likely as volume increases, payer negotiations intensify, and new competitors emerge.
- International prices are generally lower, aligned with regional healthcare policies.
- Long-term price trajectories depend on competitive landscape developments and regulatory policies.
FAQs
1. How does Vonjo compare to existing myelofibrosis treatments?
Vonjo offers an alternative for patients with severe thrombocytopenia, a population less responsive to JAK inhibitors like ruxolitinib.
2. What are the primary cost drivers for Vonjo?
Development costs for rare disease drugs, manufacturing complexity, and the limited patient population drive high prices.
3. Are there any discounts or patient assistance programs?
Most manufacturers offer patient assistance programs and negotiate discounts with payers; specifics vary across regions.
4. What is the outlook for biosimilar competition?
Biosimilars are unlikely in the near term due to the complexity of biologic manufacturing and patent protections, but this may change over a decade.
5. How will future regulations impact Vonjo pricing?
Potential price controls, value-based reimbursement policies, and policy incentives for biosimilars could influence price reductions.
Citations:
[1] IQVIA, "Global Oncology Market Forecast," 2022.
[2] Cantex Pharmaceuticals, "Vonjo (pacritinib) FDA approval," 2022.
[3] Evaluate Pharma, "Oncology Drug Market Data," 2022.
[4] U.S. FDA, "Orphan Drug Designations," 2022.
